SARS-CoV-2 Variants of Concern and Clinical Severity in the Mexican Pediatric Population.

SARS-CoV-2 Variants of Concern and Clinical Severity in the Mexican Pediatric Population.

Publication date: Sep 11, 2023

The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants of concern (VOCs) presents global heterogeneity, and their relative effect on pediatric severity is still limited. In this study, we associate VOCs with pediatric clinical severity outcomes in Mexico. Bioinformatics methods were used to characterize VOCs and single amino acid (aa) mutations in 75,348 SARS-CoV-2 genetic sequences from February 2020 to October 2022. High-predominance VOCs groups were calculated and subsequently associated with 372,989 COVID-19 clinical pediatric outcomes. We identified 21 high-frequency mutations related to Omicron lineages with an increased prevalence in pediatric sequences compared to adults. Alpha and the other lineages had a significant increase in case fatality rate (CFR), intensive critical unit (ICU) admission, and automated mechanical ventilation (AMV). Furthermore, a logistic model with age-adjusted variables estimated an increased risk of hospitalization, ICU/AMV, and death in Gamma and Alpha, in contrast to the other lineages. We found that, regardless of the VOCs lineage, infant patients presented the worst severity prognoses. Our findings improve the understanding of the impact of VOCs on pediatric patients across time, regions, and clinical outcomes. Enhanced understanding of the pediatric severity for VOCs would enable the development and improvement of public health strategies worldwide.

Open Access PDF

Concepts Keywords
Coronavirus children
February COVID-19
Hospitalization hospitalization
Mexican mortality


Type Source Name
disease VO population
disease MESH COVID-19
disease VO frequency
disease MESH death
disease VO time
disease VO USA
disease VO Severe acute respiratory syndrome coronavirus 2
disease MESH severe acute respiratory syndrome
drug DRUGBANK Coenzyme M
disease VO Glycoprotein
disease VO Envelope protein
disease VO organization
disease VO vaccine effectiveness
disease MESH influenza
pathway REACTOME Immune System
disease IDO innate immune response
disease MESH complications
disease MESH sepsis
disease MESH nosocomial infections
disease MESH syndrome
disease IDO country
disease VO vaccination coverage
disease MESH infectious diseases
disease MESH morbidity
disease IDO host

Original Article

(Visited 1 times, 1 visits today)